Share this article

Disclaimer

The following resource was developed and shared during the multi-country Mpox outbreak of clade II in 2022-2023. The current outbreak of Mpox clade I requires different considerations for patient management as clade I is considered a select agent. If you have questions related to the isolation of patients and waste management, please reach out to us here or email us at info@netec.org.

What Pediatricians Need to Know about Mpox

As the 2022 global mpox outbreak continues to spread in the U.S. and abroad, pediatricians should consider how mpox may affect their patients.

Pediatric Cases of Mpox Remain Low

Pediatric infectious disease specialists are actively monitoring the global mpox outbreak first reported in May 2022. As of August 22, 2022, there have been 42,954 cases reported worldwide, with 15,433 from the U.S. alone. See the CDC 2022 Mpox Outbreak Global Map (CDC, https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html, Accessed 8/23/2022).

Very few pediatric cases of mpox have been reported. As of July 26, 2022, the WHO is reporting 81 cases under the age of 17 globally (WHO, https://news.un.org/en/story/2022/07/1123262, accessed 8/23/22), and as of August 21, the CDC is reporting 17 cases under the age of 16 in the United States (CDC, https://www.cdc.gov/poxvirus/monkeypox/response/2022/demographics.html, Accessed 8/23/2022). Consequently, pediatric data on mpox are limited.

Pediatric Concerns for Mpox Transmission

Most cases in the current outbreak continue to be reported in men who have sex with men and spread primarily through skin-to-skin intimate contact. However, it is important to realize that this is not strictly a sexually transmitted infection; and transmission can occur in several ways. In fact, reported household transmission raises the concern that similar transmission could occur in other environments such as daycares, schools, and with contact sports. Children are susceptible to transmission through:

Pediatric Symptoms of Mpox

Most of what we know about the clinical presentation of mpox is from cases in endemic regions of Africa. Classic symptoms include fever, chills, myalgias, malaise, headaches, and lymphadenopathy, followed or accompanied by a characteristic rash that begins on the face and spreads to the extremities. Learn more about the clinical presentation and progression of mpox. (WHO, https://www.who.int/news-room/fact-sheets/detail/mpox, accessed 8/23/22)

This outbreak has turned all that on its head, as more atypical presentations are being reported (CDC, https://www.cdc.gov/mmwr/volumes/71/wr/mm7132e3.htm, 8/23/22), which can make recognition more difficult:

Data with pediatric patients are limited overall, and while the disease course is similar to adults, there are some data—primarily with Clade I (previously called the Congo Basin clade)—to suggest more severe disease and higher case fatality rate in pediatric patients (WHO, https://www.who.int/news-room/fact-sheets/detail/mpox, accessed 8/23/22), particularly those less than 8-years-old.

Complications, while rare, can occur, including:

Diagnosing Mpox in Kids

Pediatricians should have a high degree of suspicion for mpox when diagnosing a patient, particularly given the emerging atypical presentations. Pay special attention to epidemiologic risk factors, though these will shift as the disease spreads (e.g., travel is not as important a risk factor as community spread occurs).

Diagnostic testing for mpox is available through the Laboratory Response Network (LRN) or any of 5 commercial labs. The polymerase chain reaction (PCR) test involves swabbing lesions, preferably from two separate sites, as guided by local health department recommendations. If you suspect mpox, contact your state or local health department prior to specimen collection. If your health care facility is equipped to collect mpox samples, see NETEC’s learning module on how to collect an appropriate specimen for mpox virus diagnostic testing.

See NETEC’s Laboratory Resources for Mpox flyer.

While awaiting the results of a mpox diagnostic test, pediatricians may consider common differential diagnostics in children, include chickenpox, molluscum contagiosum, measles, rickettsial infections, HSV, bacterial skin infections (i.e., impetigo), cutaneous anthrax, scabies, syphilis, or cutaneous drug reactions.

Treatment and Care for Children

Treatment of mpox is primarily supportive: ensuring adequate hydration and restoring fluid losses, treatment of complications, and pain control. Antiviral medication should be considered in patients with: severe disease or associated complications, immunocompromising conditions, eczema, and other skin conditions, those under 8 years of age, and pregnant people.

Among the antiviral treatments with Expanded Access-Investigational New Drug (EA-IND) status available from the Strategic National Stockpile (SNS), tecoviromat is considered first-line treatment for mpox in both adults and children.

Other treatments may be considered in addition to tecovirimat or as an alternative (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/pediatric.html, Accessed 8/23/2022).

Mpox Vaccination for Children

There are two vaccines available for use in the prevention of mpox—currently reserved for patients who are determined to be at high risk for mpox infection. Of the two vaccines, the FDA has issued an Emergency Use Authorization (EUA) for the use of JYNNEOS:

The second vaccine, ACAM2000, can be used for the prevention of mpox under an Expanded Access-Investigational New Drug (EA-IND) protocol. However, ACAM2000 is not recommended for use in infants younger than 12 months old, or in children and adolescents with compromised immune systems, atopic dermatitis or eczema, pregnancy, cardiac disease, eye disease treated with topical steroids, or living with HIV. It should also be used in caution if close contact with immunocompromised persons is anticipated, as vaccinia can be transmitted from a vaccinated person to another individual.

Learn more about the vaccines (CDC, https://www.cdc.gov/monkeypox/vaccines/index.html, Accessed 8/23/2022).

Additional Resources for Pediatricians

Pediatric infectious disease specialists and public health partners are available to facilitate appropriate diagnostic testing, patient care, and patient and family counseling. Connect with a NETEC expert for support.

Preparation and Collection of Specimens (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/prep-collection-specimens.html, Accessed 8/23/2022)

Interim clinical guidance for the treatment of mpox (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html, Accessed 8/23/2022)

Mpox in children and adolescents (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/pediatric.html, Accessed 8/23/2022)

About the Authors

Kari A. Simonsen, MD, MBA

Kari A. Simonsen is the Chair of the Department of Pediatrics at the University of Nebraska Medical Center and Pediatrician-in-Chief of Children’s Hospital and Medical Center, Omaha, Nebraska. She is a Professor of Pediatric Infectious Diseases, and served for over a decade as division chief of Pediatric ID, as well as previous service as Hospital Epidemiologist of Children’s Hospital and Medical Center in Omaha, Nebraska.  She also previously served as Assistant Vice Chancellor for Faculty Affairs at UNMC.

 

Clayton Mowrer, DO, MBA

Clayton Mowrer is an Internal Medicine/Pediatrics Infectious Diseases fellow at the University of Nebraska Medical Center.

Ebola: NETEC has compiled clinical guidance, preparedness resources, and educational materials related to ebola to support healthcare professionals and healthcare teams seeking reliable, evidence-informed information.
Access the resource library here.

Close Welcome Bar